Driven by Covid-19 fever, Forbion notes investor interest in vaccines and new therapies as part of $557M fund
Nearly a year into the Covid-19 pandemic, a wave of investment in novel therapies and vaccines to fight the virus has continued to flow—and investors are taking notice.
Despite focusing most of its strategy on late-stage assets, Forbion has seen growing interest from investors in its $557 million Fund V in “novel medicines, vaccines and biotech solutions” to tackle COVID-19, the Euro VC firm said Tuesday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.